ACRV

Acrivon Therapeutics, Inc. (ACRV) | Rumor.io

Acrivon Therapeutics

ACRV

Attention (50-day avg)0%

Attention rank (50-day avg)#2,634

Bullish sentiment (50-day avg)93%

Price to earnings ratio-1.01

Market capitalization88.3M

Earnings per share-1.88

Dividend yield (TTM)80%

Revenue (annual)0

Net income (annual)-77.9M

Social

What share of all stock conversation is about ACRV?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% +0	0% 0

Feb 27

Acrivon Therapeutics (ACRV) is trading well below its cash value, with some investors questioning the stock's recent selloff.
The company is set to present at the TD Cowen 46th Annual Health Care Conference, potentially providing a boost to the stock.
Some investors are holding out hope for a rebound, with one predicting ACRV could reach $4 and trade at its cash value on hand.

Generated by AI

Sentiment

Of the messages about ACRV that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% 0	87.5% -12.5	78.67% -9.57
Bearish	0%	0% 0	12.5% new	21.33% +9.57

Bullish· Jan 16

$ACRV is poised for a significant price increase due to a high short float of 31% and a 60% borrow rate, leading to potential short-selling panic.
Insider buying activity is on the rise, with the CEO and COO purchasing shares, indicating confidence in the company's future prospects.
The stock's chart looks promising, with a potential breakout imminent, and a price target of $2.7, suggesting a strong upward trajectory.

Bearish· Jan 12

$ACRV's borrow rate is increasing, potentially exacerbating selling pressure.
There are concerns about management's actions, with some speculating it could be a "megadump" or a sign of poor decision-making.
The stock is predicted to decline to near $1.00 by the end of the week, with some users expressing confidence in this outcome.

Generated by AI

Topics

Of the messages about ACRV that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	69.52%
Technical Analysis	0%	0%	0%	22.62%
Analysts	0%	0%	0%	6.9%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0.97%
Macro	0%	0%	0%	0%

Announcements· Jan 8

Acrivon Therapeutics reported positive interim Phase 2b data for ACR-368 in endometrial cancer, with a 39% overall response rate.
The company plans to expand the ACR-368 trial into the European Union to accelerate patient enrollment.
Acrivon Therapeutics also announced initial clinical data for ACR-2316, its next development candidate, and ACR-6840, a potential first-in-class oral CDK11 inhibitor.

Technical Analysis· Apr 9

$ACRV is in a downtrend, with a possible reversal off a demand zone.
A long day trade EMA crossover indicator on $ACRV was triggered at $9.29 and $10.58.
$ACRV made a VWAP crossover, with a retest that held, and is showing momentum continuing with higher highs and lows.

Generated by AI

Community

Of the messages about ACRV, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	9.09%	1.59%	11.11%	15.78%
Newcomers	90.91%	98.41%	88.89%	84.22%

Jan 8

The newcomer is excited about Acrivon Therapeutics' upcoming Phase 2b update on its ACR-368 and ACR-2316 treatments for ovarian and testicular cancer.
The newcomer is expecting a short-term price swing after the news release and is planning to sell off and buy back shares.
The newcomer is optimistic about Acrivon Therapeutics' strong short-term trend breakout and bullish technical outlook, with the stock's potential to reach $3.80 or $4.

Generated by AI

News

What Makes Acrivon Therapeutics, Inc. (ACRV) a New Buy Stock

Acrivon Therapeutics, Inc. (ACRV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

14d agoYahoo Finance

Acrivon Therapeutics at 12th annual Cantor Fitzgerald conference: platform push

20d agoInvesting.com

Acrivon Therapeutics, Inc. (ACRV) Just Flashed Golden Cross Signal: Do You Buy?

26d agoYahoo Finance

Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference

WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced the company’s president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D

28d agoYahoo Finance

acrivon appoints michaela levin as chief business officer

1mo agoInvesting.com

Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer

1mo agoYahoo Finance

Also Discussed

Investors talking about ACRV also mention

#	Name	Attention
1	Immuneering Corp. Class A Common StockIMRX	0%0
2	Neumora Therapeutics, Inc. Common StockNMRA	0%0
3	Aspire Biopharma Holdings, Inc.ASBP	0%new
4	PepGen Inc.PEPG	0%new
5	Alumis Inc.ALMS	0%0
6	Roma Green Finance LimitedROMA	0%0
7	SolarMax Technology, Inc.SMXT	0%new
8	SKYX Platforms Corp.SKYX	0%0
9	Brand Engagement Network Inc.BNAI	0%+0
10	MURA - Mural Oncology plc	——

Acrivon Therapeutics, Inc.

Healthcare
Biotechnology

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology. The company develops cancer medicines using its proprietary Acrivon Predictive Precision Proteomics (AP3) platform, which is designed to match drug mechanisms with the biological drivers of each tumor and identify patients most likely to respond. Its current work centers on targeted therapies and companion diagnostics for solid tumors, with programs spanning DNA damage response and cell-cycle regulation pathways. Acrivon Therapeutics also develops its OncoSignature diagnostic approach to support patient selection in clinical development. Headquartered in Watertown, Massachusetts, Acrivon Therapeutics plays a specialized role in the biopharmaceutical market by combining drug discovery, biomarker development, and clinical research to advance more selective oncology treatments.

Website

Location

480 Arsenal Way

Watertown, MA, 02472

United States

Social

What share of all stock conversation is about ACRV?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% +0	0% 0

Feb 27

Acrivon Therapeutics (ACRV) is trading well below its cash value, with some investors questioning the stock's recent selloff.
The company is set to present at the TD Cowen 46th Annual Health Care Conference, potentially providing a boost to the stock.
Some investors are holding out hope for a rebound, with one predicting ACRV could reach $4 and trade at its cash value on hand.

Generated by AI

Sentiment

Of the messages about ACRV that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% 0	87.5% -12.5	78.67% -9.57
Bearish	0%	0% 0	12.5% new	21.33% +9.57

Bullish· Jan 16

$ACRV is poised for a significant price increase due to a high short float of 31% and a 60% borrow rate, leading to potential short-selling panic.
Insider buying activity is on the rise, with the CEO and COO purchasing shares, indicating confidence in the company's future prospects.
The stock's chart looks promising, with a potential breakout imminent, and a price target of $2.7, suggesting a strong upward trajectory.

Bearish· Jan 12

$ACRV's borrow rate is increasing, potentially exacerbating selling pressure.
There are concerns about management's actions, with some speculating it could be a "megadump" or a sign of poor decision-making.
The stock is predicted to decline to near $1.00 by the end of the week, with some users expressing confidence in this outcome.

Generated by AI

Topics

Of the messages about ACRV that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	69.52%
Technical Analysis	0%	0%	0%	22.62%
Analysts	0%	0%	0%	6.9%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0.97%
Macro	0%	0%	0%	0%

Announcements· Jan 8

Acrivon Therapeutics reported positive interim Phase 2b data for ACR-368 in endometrial cancer, with a 39% overall response rate.
The company plans to expand the ACR-368 trial into the European Union to accelerate patient enrollment.
Acrivon Therapeutics also announced initial clinical data for ACR-2316, its next development candidate, and ACR-6840, a potential first-in-class oral CDK11 inhibitor.

Technical Analysis· Apr 9

$ACRV is in a downtrend, with a possible reversal off a demand zone.
A long day trade EMA crossover indicator on $ACRV was triggered at $9.29 and $10.58.
$ACRV made a VWAP crossover, with a retest that held, and is showing momentum continuing with higher highs and lows.

Generated by AI

Community

Of the messages about ACRV, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	9.09%	1.59%	11.11%	15.78%
Newcomers	90.91%	98.41%	88.89%	84.22%

Jan 8

The newcomer is excited about Acrivon Therapeutics' upcoming Phase 2b update on its ACR-368 and ACR-2316 treatments for ovarian and testicular cancer.
The newcomer is expecting a short-term price swing after the news release and is planning to sell off and buy back shares.
The newcomer is optimistic about Acrivon Therapeutics' strong short-term trend breakout and bullish technical outlook, with the stock's potential to reach $3.80 or $4.

Generated by AI

Acrivon Therapeutics

Social

Feb 27

Bullish· Jan 16

Bearish· Jan 12

Announcements· Jan 8

Technical Analysis· Apr 9

Jan 8

What Makes Acrivon Therapeutics, Inc. (ACRV) a New Buy Stock

Acrivon Therapeutics at 12th annual Cantor Fitzgerald conference: platform push

Acrivon Therapeutics, Inc. (ACRV) Just Flashed Golden Cross Signal: Do You Buy?

Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference

acrivon appoints michaela levin as chief business officer

Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer

Also Discussed

Acrivon Therapeutics, Inc.

Company Information

Location

What Makes Acrivon Therapeutics, Inc. (ACRV) a New Buy Stock

Acrivon Therapeutics at 12th annual Cantor Fitzgerald conference: platform push

Acrivon Therapeutics, Inc. (ACRV) Just Flashed Golden Cross Signal: Do You Buy?

Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference

acrivon appoints michaela levin as chief business officer

Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer

Also Discussed

Social

Feb 27

Bullish· Jan 16

Bearish· Jan 12

Announcements· Jan 8

Technical Analysis· Apr 9

Jan 8